177Lu Dotatate (Lutathera) is a radiolabeled somatostatin analog peptide approved by the FDA for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults. Specifically, it is indicated for:
- Adult patients with foregut, midgut, and hindgut neuroendocrine tumors that show overexpression of somatostatin receptors
- Unresectable or metastatic disease that is progressive
Key details:
- 177Lu Dotatate binds to somatostatin receptors that are commonly overexpressed in GEP-NETs cells, allowing targeted delivery of radioactive Lutetium-177 to tumors
- As an intravenous radionuclide therapy, it works by emitting beta radiation to induce DNA damage and cell death in targeted tumor cells
The approval was based on the pivotal
NETTER-1 phase III trial, which demonstrated:
- Significantly longer progression-free survival with 177Lu Dotatate compared to high-dose octreotide LAR (a non-radiolabeled somatostatin analog) in progressive midgut NETs
- Objective response rates of 18% with 177Lu Dotatate versus 3% with octreotide LAR
177Lu Dotatate emits beta radiation, which penetrates just a short distance, limiting damage to nearby healthy tissues. Most common adverse effects are:
- Nausea
- Vomiting
- Lymphopenia
These are generally manageable with antiemetics, growth factors, and supportive care.
At
Elite Hormone Therapy, we offer cutting-edge peptide receptor radionuclide therapy for NETs and other neuroendocrine tumors. Our specialists have deep expertise in delivering systemic radiotherapy in a meticulously planned, precision-targeted approach to suppress tumor growth while minimizing side effects.
We conduct thorough molecular profiling to identify patients most likely to benefit from 177Lu Dotatate therapy based on somatostatin receptor status. Our technologically advanced facilities and nuclear medicine expertise allow us to deliver customized therapy with optimal accuracy.
Key elements of our approach include:
- Precision molecular diagnostics to analyze receptor status
- Personalized therapy planning and dosing using advanced software
- Coordinated supportive care before, during, and after therapy cycles
- State-of-the-art facilities and technology for safe, effective delivery
- Close monitoring, follow-up and supportive care during and after treatment
If you or a loved one has been diagnosed with a neuroendocrine tumor, consider being evaluated for 177Lu Dotatate therapy at Elite Hormone Therapy. Contact our team today to learn more about how this innovative therapy could help control the growth of inoperable or metastatic NETs.
